Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385195 | 0.93 | PDGFRB (0.44) | PDGFRBP2RY12MAPTMAPK1L3MBTL1 | |
| SCHEMBL2401520 | 0.93 | MEN1 (0.50) | PDGFRBP2RY12MAPTMAPK1L3MBTL1 | |
| SCHEMBL12251021 | 0.91 | P2RY12 (0.49) | PDGFRBP2RY12MAPTMAPK1 | |
| SCHEMBL12251020 | 0.90 | TRPV1 (0.48) | PDGFRB | |
| SCHEMBL12251049 | 0.89 | DRD2 (0.41) | PDGFRBP2RY12MAPTMAPK1L3MBTL1 | |
| SCHEMBL2383727 | 0.87 | DRD2 (0.51) | PDGFRBP2RY12MAPTMAPK1L3MBTL1 | |
| SCHEMBL12250952 | 0.86 | P2RY12 (0.41) | PDGFRBP2RY12DRD2DRD4DRD3 | |
| SCHEMBL5569274 | 0.86 | LIMK2 (0.51) | PDGFRBP2RY12MAPTMAPK1 | |
| SCHEMBL5573600 | 0.84 | TRPV1 (0.49) | PDGFRBP2RY12 | |
| SCHEMBL2385769 | 0.81 | PDGFRB (0.44) | PDGFRBP2RY12MAPTMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013156-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275952-A1 | Tie-2 Modulators and Methods of Use | TIE1, TEK, KDR | PDGFRB 45/4885P2RY12 1298/4885MAPT 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.